Dyne Therapeutics (DYN) Cash & Equivalents (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Cash & Equivalents data on file, last reported at $753.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 59.47% year-over-year to $753.1 million in Q1 2026; TTM through Mar 2026 was $753.1 million, a 59.47% increase from a year earlier, with the FY2025 full-year figure at $893.4 million, up 105.16% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $753.1 million, down from $893.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for DYN reached as high as $893.4 million in Q4 2025 and fell as low as $121.6 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $361.2 million across 5 years, with a median of $272.0 million in 2024.
• Across the five-year window, Cash & Equivalents slumped 59.12% in 2022 and surged 308.48% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $172.1 million in 2022, then fell by 29.35% to $121.6 million in 2023, then surged by 258.02% to $435.4 million in 2024, then surged by 105.16% to $893.4 million in 2025, then slipped by 15.7% to $753.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $753.1 million in Q1 2026, $893.4 million in Q4 2025, and $573.6 million in Q3 2025.